Merck and GSK to Rule Prophylactic Cancer Vaccine Market
An analysis of the prophylactic cancer vaccines in clinical trials reveals that no new player is expected to hit the market for another five years at least. With no new player in the picture, Merck and GSK will continue to enjoy their market supremacy. Merck’s efforts for expanding its market presence can be deciphered by a number of studies in various phases of clinical trials. In a phase-4 clinical trial expected to be concluded by January 2014, it is evaluating...
View full press release